CAJ | 학술논문

目的:研究脑梗死患者抑郁焦虑的发生率以及赛乐特的治疗效果.方法:对110例脑梗死患者用症状自评量表(SCL-90)、抑郁自评量表(SDS)、焦虑自评量表(SAS)和欧洲卒中评分量表(ESS)进行评定,SDS或SAS评定标准分50分以上者可诊断为脑梗死合并抑郁、焦虑.赛乐特治疗4周后.再行SDS、SAS和ESS评定.结果:110例脑梗死患者中50例(45%)并发抑郁或焦虑,赛乐特治疗4周后50例中42例评分恢复正常(<50分),ESS平均分由(71.3±6.2)分增加为(87.2±7.1)分.结论:脑梗死后出现抑郁焦虑的发病率高,与ESS呈明显负相关,赛乐特治疗是有效的.
목적:연구뇌경사환자억욱초필적발생솔이급새악특적치료효과.방법:대110례뇌경사환자용증상자평량표(SCL-90)、억욱자평량표(SDS)、초필자평량표(SAS)화구주졸중평분량표(ESS)진행평정,SDS혹SAS평정표준분50분이상자가진단위뇌경사합병억욱、초필.새악특치료4주후.재행SDS、SAS화ESS평정.결과:110례뇌경사환자중50례(45%)병발억욱혹초필,새악특치료4주후50례중42례평분회복정상(<50분),ESS평균분유(71.3±6.2)분증가위(87.2±7.1)분.결론:뇌경사후출현억욱초필적발병솔고,여ESS정명현부상관,새악특치료시유효적.
Objective: To investigate the incidence rate of anxiety or depression in patients with cerebral infarction and the curative effect of Seroxat. Methods: 110 patients with cerebral infarction were assessed with Symptom Checklist 90 (SCL-90), Self Rating Anxiety Scale (SAS), Self Rating Depression Scale (SDS) and European Stroke Scale (ESS). After taking Seroxat for 4 weeks, the patients with anxiety or depression were reassessed. Results: 50 cases of 110 cerebral infarction patients (45%) were diagnosed anxiety or depression. After taking Seroxat for 4 weeks, the SAS and SDS score of 42 cases appeared normal(<50), the average ESS score increased from(71.3±6.2)to(87.2±7.1). Conclusion: There is a high incidence of depression or anxiety after cerebral infarction, which had a negative correlation with ESS. Scroxat has a notable curative effect.